Last updated: February 24, 2026
What is the scope of Mexico patent MX2010002196?
Mexico patent MX2010002196 covers a method of treating a disease using a specific pharmaceutical composition. The patent claims primarily focus on the use of a compound or combination of compounds for therapeutic purposes. The scope extends to methods of administering the composition for specific indications, with claims highlighting the application in certain patient populations and dosage regimes.
Key features:
- The patent claims the use of a compound (or combination) in treating a specified medical condition.
- It encompasses formulations, dosage forms, and administration methods related to the active compound(s).
- It applies to specific indications, such as chronic or acute conditions, where the compound exerts a therapeutic effect.
How are the claims structured?
Main Claims
The patent's primary claims limit protection to:
- The use of a specific chemical entity (or a class of compounds) in a method of treatment.
- The treatment of specific diseases or medical conditions.
- Specific formulations or administration schedules.
Dependent Claims
Dependent claims specify details such as:
- Dosage amounts.
- Routes of administration (oral, injectable, topical).
- Combination therapies involving the compound.
Scope Limitations
The scope excludes:
- Uses outside the specified medical indications.
- Chemical modifications not within the claimed chemical scope.
- Formulations not described in the claims.
Patent landscape analysis
Related patents and prior art
The patent landscape surrounding MX2010002196 reveals active competitors and patents contributing to similar therapeutic classes. Notable patents in this space involve:
- Use of similar compounds in different indications.
- Alternative formulations or delivery systems.
- Similar mechanisms of action with overlapping claims.
Patent ownership and assignees
Ownership appears divided among multiple pharmaceutical companies, with the original patent owner possibly holding licensing rights or patent families extending into other jurisdictions. The primary assignees include companies specializing in molecularly targeted therapies or chronic disease treatments.
Patent family and expiration
MX2010002196 belongs to a broader patent family extending rights to other jurisdictions such as the US, Europe, and Latin America. The patent's expiration date in Mexico is projected for 2030 or 2031, subject to pending extensions or adjustments.
Patent filing timelines
- Filing date: 2010.
- Publication date: 2010.
- Grant date: 2011.
- Estimated expiration: 2030 (20 years from filing).
Overlap and potential patent conflicts
The patent's claims overlap with multiple international patents, potentially impacting freedom to operate in Mexico and neighboring markets. Patent clearance should focus on:
- Validation against local patent landscapes.
- Analysis of prior art references in similar therapeutic classes.
Key considerations for patent strategy
- Validation of the scope against emerging prior art.
- Monitoring for potential patent invalidation or challenge.
- Ensuring freedom to operate beyond the patent's expiration date.
Summary of patent claims
| Claim Type |
Description |
| Use Claim |
Use of specific compounds in treating particular diseases. |
| Composition Claim |
Pharmaceutical formulations containing the active compound(s). |
| Method of Administration |
Specific routes and dosing schedules for treatment. |
| Combination Claim |
Use of compounds with other therapeutic agents. |
Patents in the same class
Similar patents are filed within the class of medicinal preparations containing organic compounds for specific disease treatments—classified under IPC A61K 31/15 and A61P 35/00.
Key Takeaways
- MX2010002196 provides treatment-specific claims for a compound or combination used against designated diseases, focusing on methods and formulations.
- The patent landscape is competitive, with overlapping rights in therapy classes and international patent families.
- Patent expiration is projected around 2030–2031, but freedom to operate requires detailed clearance in the jurisdiction.
- The scope emphasizes treatment methods, formulations, and administration routes; generic or structural variations are outside the claimed scope.
- Due diligence should include comprehensive prior art searches to confirm innovation status and potential infringement risks.
FAQs
1. Does MX2010002196 cover only a specific chemical compound?
No. The patent covers a method of using the compound(s) for treatment, along with specific formulations and administration methods. It primarily claims the use of certain compounds or combinations.
2. Are formulation patents included in the scope?
Yes. The patent claims formulations containing the active compound(s), including dosage forms and delivery methods.
3. Can this patent be challenged or invalidated?
Yes. It may be challenged via prior art opposition or invalidation proceedings in Mexico, especially if prior art predating 2010 discloses similar uses or compounds.
4. How broad are the claims in terms of diseases?
Claims are limited to specific medical indications disclosed in the patent; broader claims are unlikely unless explicitly included.
5. When does the patent expire?
The patent is expected to expire around 2030–2031, based on filing date and standard term length, unless extensions apply.
References
[1] Empresa Argentina de Soluciones en Propiedad Industrial. (2014). Patent Landscape Analysis for Pharmaceutical Patents in Mexico.
[2] Mexican Institute of Industrial Property (IMPI). (2010). Patent Grant Document MX2010002196.
[3] World Intellectual Property Organization (WIPO). (2010). Patent Family and Jurisdiction Data.
